Literature DB >> 16799173

Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.

Marlies Noordzij1, Johanna C Korevaar, Willem J Bos, Elisabeth W Boeschoten, Friedo W Dekker, Patrick M Bossuyt, Raymond T Krediet.   

Abstract

BACKGROUND: The K/DOQI guideline for bone metabolism and disease in chronic kidney disease is predominantly based on studies in haemodialysis (HD) patients. However, in clinical practice, this guideline is also applied to peritoneal dialysis (PD) patients. To validate the implementation of this guideline in PD patients, we evaluated the associations between plasma concentrations outside the K/DOQI-targets and the risk of cardiovascular morbidity and mortality in incident PD patients compared with HD patients.
METHODS: In a large prospective multicentre study in the Netherlands (The Netherlands Cooperative Study on the Adequacy of Dialysis, NECOSAD), we included patients starting PD or HD between 1997 and 2004. Relative risk of cardiovascular morbidity and mortality were estimated using time-dependent Cox regression modelling.
RESULTS: We included 586 PD patients with mean age 52 +/- 15 years (66% males) and 1043 HD patients with mean age 63 +/- 14 years (58% males). Cardiovascular disease (CVD) was the reason for hospitalization in 102 PD and 271 HD patients. In HD patients, the relative risk of CVD-related hospitalization increased with elevated plasma calcium concentrations (hazard ratio: 1.4; 95% CI: 1.1-1.9). Cardiovascular mortality was significantly higher for phosphorus concentrations above the K/DOQI-threshold in PD (2.4; 95% CI: 1.3-4.2) and HD patients (1.5; 95% CI: 1.1-2.1), and for elevated Ca x P in PD (2.2; 95% CI: 1.3-3.8) and HD patients (1.5; 95% CI: 1.1-2.1).
CONCLUSIONS: Plasma calcium concentrations above the K/DOQI-threshold increase the relative risk of CVD-related hospitalization in HD patients. Associations with cardiovascular mortality were more pronounced. Both in PD and HD patients with elevated plasma phosphorus and Ca x P concentrations, the cardiovascular mortality risk is increased. Therefore, it seems appropriate to adopt the current guideline in PD patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799173     DOI: 10.1093/ndt/gfl257

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  27 in total

Review 1.  Arterial calcification in chronic kidney disease: key roles for calcium and phosphate.

Authors:  Catherine M Shanahan; Matthew H Crouthamel; Alexander Kapustin; Cecilia M Giachelli
Journal:  Circ Res       Date:  2011-09-02       Impact factor: 17.367

2.  Coronary Artery Calcification in Hemodialysis and Peritoneal Dialysis.

Authors:  Thijs T Jansz; Franka E van Reekum; Akin Özyilmaz; Pim A de Jong; Franciscus T J Boereboom; Tiny Hoekstra; Marianne C Verhaar; Brigit C van Jaarsveld
Journal:  Am J Nephrol       Date:  2018-11-13       Impact factor: 3.754

3.  Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis.

Authors:  Connie M Rhee; Miklos Z Molnar; Wei Ling Lau; Vanessa Ravel; Csaba P Kovesdy; Rajnish Mehrotra; Kamyar Kalantar-Zadeh
Journal:  Perit Dial Int       Date:  2014-01-02       Impact factor: 1.756

4.  Parathyroid ultrasonography and bone metabolic profile of patients on dialysis with hyperparathyroidism.

Authors:  Cláudia Ribeiro; Maria Goretti Moreira Guimarães Penido; Milena Maria Moreira Guimarães; Marcelo de Sousa Tavares; Bruno das Neves Souza; Anderson Ferreira Leite; Leonardo Martins Caldeira de Deus; Lucas José de Campos Machado
Journal:  World J Nephrol       Date:  2016-09-06

5.  Comparison and causes of transfer from one dialysis modality to another.

Authors:  Aydin Unal; Ismail Kocyigit; Murat Hayri Sipahioglu; Bulent Tokgoz; Oktay Oymak; Cengiz Utas
Journal:  Int Urol Nephrol       Date:  2010-09-10       Impact factor: 2.370

6.  Peritoneal phosphate clearance is influenced by peritoneal dialysis modality, independent of peritoneal transport characteristics.

Authors:  Sunil V Badve; Deborah L Zimmerman; Greg A Knoll; Kevin D Burns; Brendan B McCormick
Journal:  Clin J Am Soc Nephrol       Date:  2008-09-24       Impact factor: 8.237

7.  Is residual renal function and better phosphate control in peritoneal dialysis an answer for the lower prevalence of valve calcification compared to hemodialysis patients?

Authors:  Merita Rroji; Saimir Seferi; Majlinda Cafka; Elizana Petrela; Erjola Likaj; Myftar Barbullushi; Nestor Thereska; Goce Spasovski
Journal:  Int Urol Nephrol       Date:  2013-04-17       Impact factor: 2.370

8.  Phosphate Removal by Peritoneal Dialysis: The Effect of Transporter Status and Peritoneal Dialysis Prescription.

Authors:  Cecile Courivaud; Andrew Davenport
Journal:  Perit Dial Int       Date:  2015-07-29       Impact factor: 1.756

9.  Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes.

Authors:  Shen Hui Chuang; Hung Chew Wong; Anantharaman Vathsala; Evan Lee; Priscilla Pei Ching How
Journal:  Singapore Med J       Date:  2015-12-29       Impact factor: 1.858

10.  Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER--a multicentre, prospective, observational cohort study.

Authors:  Rafael Pérez-García; Alejandro Martín-Malo; Joan Fort; Xavier Cuevas; Fina Lladós; Javier Lozano; Fernando García
Journal:  Nephrol Dial Transplant       Date:  2008-11-21       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.